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PROJECT SUMMARY 
 
The NIHR Trauma Management MedTech Co-operative 
(NIHR Trauma MIC) has collaborated with Cerebrotech   
Medical Systems in the evaluation of the Cerebrotech Visor, 
a non-invasive device consisting of a scanner, console and  
disposables. The device uses Volumetric Impedance     
Phase-shift Spectroscopy (VIPS™) technology which         
provides real-time assessment of the brain’s status following 
strokes and other brain injury, potentially facilitating earlier 
intervention. Changes in the brain’s fluids, such as those  
involved in stroke, bleeding, or oedema, can be detected by 
monitoring fluctuations in intracranial electrical properties, 
called bioimpedance. These changes are detected by          
measuring the alterations in low-power (less than that of a 
mobile phone) radio waves generated by the device as they 
pass through the head. 
 
CLINICAL NEED 
 
According to NICE Clinical Guideline 176 (2014):  
  
Head injury is the commonest cause of death and        
disability in people aged 1–40 years in the UK. Each year, 
1.4 million people attend emergency departments in    
England and Wales with a recent head injury. Annually, 
about 200,000 people are admitted to hospital with head 
injury, of these, one-fifth have features suggesting skull 
fracture or have evidence of brain damage.  
 
Emergency departments see a large number of patients   
with minor or mild brain injuries such as stroke, and need to         
rapidly identify the small percentage of people who may 
have or will go on to develop serious acute intracranial            
pathologies. Providing a fast, non-invasive method of               
detecting complications in these patients could greatly            
improve the efficiency of treatment for head injury. 
 
THE SOLUTION 
 
Cerebrotech Visor, utilizing VIPS, is a bioimpedance               
spectroscopy device that non-invasively detects changes in 
intracranial fluids. It is indicated for patients who are at risk 
for cerebral oedema and is intended as an aid to              
physiologic assessment in conjunction with clinical               
judgment and current standards of care. In addition, the    
Visor non-invasively detects bioimpedance asymmetry,   
including asymmetry associated with large acute ischemic 
stroke in patients who are being evaluated for acute stroke. 
Because the Visor is robust, portable, and non-invasive, it 
can be used as a valuable adjunctive clinical monitoring    
instrument in a variety of settings  
 
HOW WE SUPPORTED 
 Provided advice pertaining to the introduction of the 
Visor into European markets, and associated             
product beta testing 
 Supported applications for grant funding 
 Undertook a feasibility study in healthy volunteers 
to determine how changes in head position alter 
the device readings 
 Orchestrated a usability study to assess how nursing 
and clinical staff experienced fitting the device onto a 
simulated patient 
 
Additionally, we facilitated a study, in collaboration with 
Coventry University, to investigate the usability of the  
device with 16 paramedics (consisting of lecturers and 
second year paramedic students) within Coventry            
University’s Science and Health Building’s ambulance 
simulator facility. Assistance provided encompassed: 
 
 Usability testing strategy and plan: formative 
(observational) study 
 Evaluation and risk assessment of the user interface 
(UI) 
 Recruitment of representative test participants 
 Relevant documentation preparation e.g. consent 
forms 
 Effective moderation of the usability test 
 Data management, analysis, and UI recommendations 
 
The results of the usability work have led to valuable             
feedback, and ongoing improvements being implemented into 
the device.  
 
The device is CE marked and cleared by the U.S. Food and 
Drug Administration.  
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